Use of choline comprising nutritional supplements with analgesic effects in pain caused by fibromyalgia syndrome

WO2024263144A1PCT designated stage Publication Date: 2024-12-26DOKUZ EYLUL UNIVERSITESI REKTORLUGU +3
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/TR2024/050694
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2024-06-20
Publication Date
2024-12-26

Smart Images

  • Figure TR2024050694_26122024_PF_FP_ABST
    Figure TR2024050694_26122024_PF_FP_ABST
Patent Text Reader

Abstract

This invention relates to the use of choline containing nutritional supplements, in which it is suggested that choline and choline comprising nutritional supplements can be repositioned for use in FMS-induced pain as an additive treatment to current medications, since choline deficiency also plays a role in pain caused by fibromyalgia syndrome (FMS).
Need to check novelty before this filing date? Find Prior Art

Description

[0001] USE OF CHOLINE COMPRISING NUTRITIONAL SUPPLEMENTS WITH ANALGESIC EFFECTS IN PAIN CAUSED BY FIBROMYALGIA SYNDROME

[0002] Field of the Invention

[0003] The invention relates to the use of choline containing nutritional supplements, in which it is suggested that choline and choline containing nutritional supplements can be repositioned in treatment to be used in pain caused by FMS, since choline deficiency also plays a role in pain caused by fibromyalgia syndrome (FMS).

[0004] Prior Art

[0005] Fibromyalgia syndrome (FMS) is a chronic pain syndrome that affects muscles, ligaments, and tendons which can also be defined as "myalgia", and is characterized by widespread muscle aches and hypersensitivity in many parts of the body. Its name is a combination of the words "fibro-fibrous tissue, connective tissue", "myo-muscle" and "algia-pain". Although arthritis (inflammatory rheumatic disease) is thought to be a similar condition, inflammation has not been shown in joints, muscles and other tissues. However, it affects the life of the person negatively due to the severe pain and fatigue it causes. Fibromyalgia is a chronic pain syndrome which can be accompanied by mental disorders such as sleep disturbance, headache, anxiety and depression.

[0006] Fibromyalgia the second most common rheumatic disease, accounting for 20% of all rheumatologic diagnoses. Its prevalence in society has been defined as 0.5-5% in various studies. However, 2% of female fibromyalgia patients and 0.15% of male patients can be diagnosed. The ratio of women to men in the society is 3:1. This ratio is most commonly observed in middle-aged individuals but can also be seen in children and older adults. The most common age range for its occurrence is between 40 and 50 years, though it can also affect individuals under 40 and over 60. In our country, its prevalence is 3.6% among women aged 20-64 and 0.9% among women aged 20-29. In patients with fibromyalgia syndrome, widespread pain or regional pain complaints are observed. Treatments for patients with Fibromyalgia Syndrome require a team work that includes physical therapist, physiotherapist and psychologist. Since underlying causes for FMS has not been proven yet, its treatment has also been shaped through different mechanisms and complaints. Simple analgesics, nonsteroidal anti-inflammatory drugs, muscle relaxants are generally recommended for pain. In addition to drug use, exercise is recommended. There is no standard treatment for FMS. The main goal of treatment in FMS is to improve pain and sleep and restore impaired functions. In addition to pharmacological treatment, non-pharmacological treatments such as exercise, cognitive and behavioral treatment, and physical therapy are also applied in the treatment. Several drugs can often be used alone or in combination to relieve FMS symptoms. Approved medications for FMS include selective serotonin and norepinephrine reuptake inhibitors (SNRIs) likeduloxetine and milnacipran, and anticonvulsants like pregabal in. (Maffei, 2020).

[0007] There is no specific pharmacological treatment for FMS; therefore, several drugs are often used alone or in combination to relieve FMS symptoms. These drugs are limited to selective serotonin and norepinephrine reuptake inhibitors (SNRIs), duloxetine and milnacipran, and pregabalin asan anticonvulsant which has been approved by the U.S. Food and Drug Administration in the United States (Maffei, 2020). FMS is also included in the indications of commercial preparations of these active substances included in the marketing authorizations in our country. However, despite all these treatments, there are cases where success cannot be achieved in the treatment of FMS.

[0008] In the invention, it is recommended to use choline or choline containing nutritional supplement with analgesic effect for decreasingFMS-related pain. Cholinergic system activation is known to produce analgesic effects in various acute or chronic pain models in both animals and humans (Bartolini et al., 1992; Gurun et al., 1997; Yaksh et al., 1995). It is also reported that choline is effective in reducing the dose of aspirin and morphine in acute and inflammatory pain models (Pavlov et al., 2003). It is stated that a7nAChR agonists and positive allosteric modulators (i.e. choline) may be potential drug targets in the treatment of neuroinflam matory and neuropathic pain. It was determined for the first time in our study that the blood choline levels were lower in patients diagnosed with FMS compared to the healthy controls in which also found to be related to FMS-induced pain. These findings also contribute to the physiopathology of FMS, which is still not clearly explained. In line with these results, the use of choline, choline cholinergic drugsand choline containing nutritional supplements in FMS will take a part as an supportive treatment of patients.

[0009] In the state of the art, there is no explanation regarding the technical features of the invention that is the subject of the application and the technical effects of the invention that is the subject of the application. In current practices, the use of choline containing nutritional supplements for the treatment of FMS- related pain is not encountered.

[0010] Detailed Description of the Invention

[0011] The use of a choline-containing dietary supplement with analgesic effects for alleviating FMS-related pain is illustrated in the attached figures as follows: Figure 1 : The graph of serum total choline levels (uM) in experimental groups.

[0012] This invention proposes the use of choline and choline containing nutritional supplements in the treatment of pain caused by fibromyalgia syndrome (FMS), suggesting that choline deficiency may also play a role in FMS-related pain, advocating for the use of choline comprising nutritional supplements to be repositioned in the treatment of pain caused by FMS, characterized by;

[0013] - The use of choline and choline containing chemical substances, known as 'brain doping' and used to enhance attention, memory, creativity, and motivation, as analgesic drugs for pain caused by fibromyalgia syndrome (FMS),

[0014] - The use of choline containing nutritional supplements (such as choline, phosphatidylcholine, citicoline, CDP-choline, etc.) for the treatment of fibromyalgia syndrome (FMS).

[0015] It is determined that the use of choline containing nutritional supplement with analgesic effect in the FMS-related pain, which is the subject of the invention, will have an effect on the reduction of pain, due to the choline levels measured from the blood in patients diagnosed with FMS are lower than the controls. During the research conducted for the invention, cholinergic system activation is known to produce analgesic effects in various acute or chronic pain models in both animals and humans (Bartolini et al., 1992; Gurun et al., 1997; Yaksh et al., 1995). It is also reported that choline is effective in reducing the dose of aspirin and morphine in acute and inflammatory pain models (Pavlov et al., 2003). It is stated that a7nAChR agonists and positive allosteric modulators may be potential drug targets in the treatment of neuroinflammatory and neuropathic pain. With this invention, it has been discovered for the first time in our study that patients diagnosed with fibromyalgia syndrome (FMS) have lower levels of choline measured in their blood compared to controls, and its role in pain caused by FMS has been identified. Thus, an additional contribution was made to the physiopathology of FMS, which is still unknown about its physiopathology. In line with these results, the use of choline, choline comprising substances and choline comprising nutritional supplements in FMS will contribute to the treatment of patients.

[0016] This study, which is an application of the invention, has shown for the first time that serum choline levels are lower in volunteers with FMS compared to healthy controls. The data obtained from this observational study suggests that supplemental choline, used in various conditions externally, can also contribute as an additional treatment in the treatment of patients with fibromyalgia syndrome (FMS).

[0017] The technical issue in this study which is part of an application of the invention is achieving success in the treatment of patients with fibromyalgia syndrome (FMS), with the conclusion of FMS patients having lower choline levels compared to healthy controls in our study named “Fibromiyalji sendromlu hastalarda Plazma Kolin duzeyleri ve Leptin ile ili§kisi; olgu-kontrol gah§masi“ which is supported by our clinical study numbered 2020. KB. SAG.014 by Dokuz Eylul Universitesi Bilimsel Ara§tirma Projeleri. A graph showing our clinical research results is presented (Figure 1) for the invention which is the subject of the application. Mann Whitney II test was used to compare the two groups (p<0.01). The method of solving the technical problem is to verify this result with a Clinical Drug Trial that is in the planning phase. For this purpose, the research team plans to confirm the efficacy of choline in FMS by comparing a group in which choline is administered in addition to routine treatment and a group in which choline is not administered in patients with FMS.

Claims

CLAIMS1. Use of choline and a choline-containing dietary supplement, wherein it is proposed that choline and choline-containing dietary supplements can be repositioned in therapy for use in pain caused by FMS, as choline deficiency also plays a role in pain caused by fibromyalgia syndrome (FMS), characterized in that;- The use of choline and choline-containing chemicals used as brain doping and attention, memory, creativity and motivation enhancer) as an analgesic drug in FMS-induced pain, - The use of nutritional supplements containing choline (such as choline, phosphatidylcholine, citicoline, CDP-choline) in the treatment of FMS.